Hair Restore MML ( Minoxidil 3% / Melatonin 0.2% / Latanoprost 0.01%) Scalp Solution

Minoxidil
Oral minoxidil (Loniten) is an antihypertensive agent; topical minoxidil (Rogaine) is used for alopecia. Topical minoxidil is likely effective in producing moderate hair growth in approximately 30% of men and 60% of women with common hereditary hair loss. Lesser growth or a halt in the worsening of alopecia are also frequent outcomes. Due to its potency and adverse reactions, oral minoxidil is used mainly for patients with severe, drug-resistant forms of hypertension. Tolerance to prolonged therapy with oral minoxidil does not appear to be a problem. Although the oral dosage form was originally approved in October 1979 for use in hypertension, minoxidil was first discovered in 1965. In August 1988 the topical formulation was approved for alopecia. After declining Upjohn permission to market topical minoxidil as a non-prescription drug in July 1994, the 2% topical solution was subsequently approved for over-the-counter use in men with alopecia in February 1996. In September 1996, Pharmacia and Upjohn petitioned the FDA to increase the topical solution formulation from 2% to 5%; the higher-strength solution has been shown to elicit a more rapid hair growth response (8 weeks vs. 16 weeks) and to regrow an average of 45% more hair than Rogaine Regular Strength.2The 5% topical solution (Rogaine Extra Strength) for common hereditary hair loss was approved FDA in November 1997. Approval to market a 2% topical solution to women was granted in October 1996. Minoxidil foam (Men's Rogaine Foam) was approved for men in January 2006; potential advantages over the solution formulation include the absence of propylene glycol (potential irritant), the ability to limit the spread of medication, and less time to dry after application.

Melatonin
Melatonin may provide some benefits and few risks for the short-term treatment of sleep irregularities in pediatric patients with neurodevelopmental disorders. In pediatric patients, there is a role for the use of melatonin in children and adolescents with autism spectrum disorder (ASD) who have not responded to behavioral strategies to improve sleep. Melatonin also has orphan drug status for neonatal hypoxic-ischemic encephalopathy. Although considered a dietary supplement in the U.S., melatonin is available by prescription in Europe under the brand name Circadin as a short-term monotherapy treatment for primary insomnia characterized by the poor quality of sleep in patients 55 years of age or more. According to the British Association for Psychopharmacology guidelines, extended-release melatonin is the first-choice treatment when a hypnotic is indicated in patients over 55 years of age.

Topical melatonin solutions have been tried and shown to be effective in the treatment of scalp seborrheic dermatitis and androgenetic alopecia.

Latanoprost
Latanoprost, an analog of prostaglandin F2alpha, is a prodrug used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Studies have shown that latanoprost administered once daily is at least as effective as timolol in lowering intraocular pressure. When latanoprost and timolol were used in combination, a complete or almost complete additive effect in reducing intraocular pressure has been observed. Treatment has been associated with increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes.